BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 28829745)

  • 1. Everolimus-eluting bioresorbable scaffolds in patients with coronary artery disease: results from the German-Austrian ABSORB RegIstRy (GABI-R).
    Nef HM; Wiebe J; Kastner J; Mehilli J; Muenzel T; Naber C; Neumann T; Richardt G; Schmermund A; Woehrle J; Zahn R; Riemer T; Achenbach S; Hamm CW
    EuroIntervention; 2017 Dec; 13(11):1311-1318. PubMed ID: 28829745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical restenosis and its predictors after implantation of everolimus-eluting bioresorbable vascular scaffolds: results from GABI-R.
    Mehilli J; Achenbach S; Woehrle J; Baquet M; Riemer T; Muenzel T; Nef H; Naber C; Richardt G; Zahn R; Gori T; Neumann T; Kastner J; Schmermund A; Hamm C
    EuroIntervention; 2017 Dec; 13(11):1319-1326. PubMed ID: 28649953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical results of bioresorbable drug-eluting scaffolds in short and long coronary artery lesions using the PSP technique.
    Reichart C; Wöhrle J; Markovic S; Rottbauer W; Seeger J
    BMC Cardiovasc Disord; 2019 Jan; 19(1):22. PubMed ID: 30658574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus-eluting bioresorbable scaffolds for treatment of coronary artery disease in patients with diabetes mellitus: the midterm follow-up of the prospective ABSORB DM Benelux study.
    Hommels TM; Hermanides RS; Rasoul S; Berta B; IJsselmuiden AJJ; Jessurun GAJ; Benit E; Pereira B; De Luca G; Kedhi E
    Cardiovasc Diabetol; 2019 Mar; 18(1):25. PubMed ID: 30851731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mid- to Long-Term Clinical Outcomes of Patients Treated With the Everolimus-Eluting Bioresorbable Vascular Scaffold: The BVS Expand Registry.
    Felix CM; Fam JM; Diletti R; Ishibashi Y; Karanasos A; Everaert BR; van Mieghem NM; Daemen J; de Jaegere PP; Zijlstra F; Regar ES; Onuma Y; van Geuns RJ
    JACC Cardiovasc Interv; 2016 Aug; 9(16):1652-63. PubMed ID: 27476094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Efficacy and Safety of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents: A Meta-Analysis of Randomized Trials.
    Mahmoud AN; Barakat AF; Elgendy AY; Schneibel E; Mentias A; Abuzaid A; Elgendy IY
    Circ Cardiovasc Interv; 2017 May; 10(5):. PubMed ID: 28468954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions: A Subanalysis of the International, Multicenter GHOST-EU Registry.
    Geraci S; Kawamoto H; Caramanno G; Ruparelia N; Capodanno D; Brugaletta S; Gori T; Nef H; Sabate M; Mehilli J; Lesiak M; Naber C; Di Mario C; Capranzano P; Wiebe J; Araszkiewicz A; Pyxaras S; Mattesini A; Münzel T; Tamburino C; Colombo A; Latib A
    JACC Cardiovasc Interv; 2017 Mar; 10(6):560-568. PubMed ID: 28259663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
    Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D
    JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1-year clinical outcomes of diabetic patients treated with everolimus-eluting bioresorbable vascular scaffolds: a pooled analysis of the ABSORB and the SPIRIT trials.
    Muramatsu T; Onuma Y; van Geuns RJ; Chevalier B; Patel TM; Seth A; Diletti R; García-García HM; Dorange CC; Veldhof S; Cheong WF; Ozaki Y; Whitbourn R; Bartorelli A; Stone GW; Abizaid A; Serruys PW; ; ; ; ; ;
    JACC Cardiovasc Interv; 2014 May; 7(5):482-93. PubMed ID: 24746650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of randomised trials.
    Cassese S; Byrne RA; Jüni P; Wykrzykowska JJ; Puricel S; Ndrepepa G; Schunkert H; Fusaro M; Cook S; Kimura T; Henriques JPS; Serruys PW; Windecker S; Kastrati A
    EuroIntervention; 2018 Jan; 13(13):1565-1573. PubMed ID: 28671552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus- Versus Novolimus-Eluting Bioresorbable Scaffolds for the Treatment of Coronary Artery Disease: A Matched Comparison.
    Wiebe J; Dörr O; Ilstad H; Husser O; Liebetrau C; Boeder N; Bauer T; Möllmann H; Kastrati A; Hamm CW; Nef HM
    JACC Cardiovasc Interv; 2017 Mar; 10(5):477-485. PubMed ID: 28216214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus-eluting bioresorbable scaffold implantation for the treatment of bifurcation lesions - Implications from early clinical experience during daily practice.
    Wiebe J; Dörr O; Bauer T; Liebetrau C; Boeder N; Möllmann H; Hamm CW; Nef HM
    Cardiovasc Revasc Med; 2016; 17(5):313-7. PubMed ID: 27085220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the short- and long-term safety and therapy outcomes of the everolimus-eluting bioresorbable vascular scaffold system in patients with coronary artery stenosis: Rationale and design of the German-Austrian ABSORB RegIstRy (GABI-R).
    Nef H; Wiebe J; Achenbach S; Münzel T; Naber C; Richardt G; Mehilli J; Wöhrle J; Neumann T; Biermann J; Zahn R; Kastner J; Schmermund A; Pfannebecker T; Schneider S; Limbourg T; Hamm CW
    Cardiovasc Revasc Med; 2016; 17(1):34-7. PubMed ID: 26431767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 6-Month Clinical and Angiographic Outcomes of a Novel Radiopaque Sirolimus-Eluting Bioresorbable Vascular Scaffold: The FANTOM II Study.
    Abizaid A; Carrié D; Frey N; Lutz M; Weber-Albers J; Dudek D; Chevalier B; Weng SC; Costa RA; Anderson J; Stone GW;
    JACC Cardiovasc Interv; 2017 Sep; 10(18):1832-1838. PubMed ID: 28935075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of the Absorb Everolimus-Eluting Bioresorbable Scaffold for Treatment of Patients With Diabetes Mellitus: Results of the Absorb Diabetic Substudy.
    Kereiakes DJ; Ellis SG; Kimura T; Abizaid A; Zhao W; Veldhof S; Vu MT; Zhang Z; Onuma Y; Chevalier B; Serruys PW; Stone GW
    JACC Cardiovasc Interv; 2017 Jan; 10(1):42-49. PubMed ID: 28017311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Clinical Outcomes of Patients Treated With Everolimus-Eluting Bioresorbable Stents in Routine Practice: 2-Year Results of the ISAR-ABSORB Registry.
    Wiebe J; Hoppmann P; Colleran R; Kufner S; Valeskini M; Cassese S; Schneider S; Joner M; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA
    JACC Cardiovasc Interv; 2017 Jun; 10(12):1222-1229. PubMed ID: 28641842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Outcomes of Absorb Bioresorbable Vascular Scaffold vs. Everolimus-Eluting Metallic Stent - A Randomized Comparison Through 5 Years in Japan.
    Kozuma K; Tanabe K; Hamazaki Y; Okamura T; Ando J; Ikari Y; Nakagawa Y; Kusano H; Ediebah D; Kimura T;
    Circ J; 2020 Apr; 84(5):733-741. PubMed ID: 32213737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanded clinical use of everolimus eluting bioresorbable vascular scaffolds for treatment of coronary artery disease.
    Diletti R; Ishibashi Y; Felix C; Onuma Y; Nakatani S; van Mieghem NM; Regar E; Valgimigli M; de Jaegere PP; van Ditzhuijzen N; Fam JM; Ligthart JMR; Lenzen MJ; Serruys PW; Zijlstra F; Jan van Geuns R
    Catheter Cardiovasc Interv; 2017 Jul; 90(1):58-69. PubMed ID: 27896897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective evaluation of a standardized strategy for the use of a polymeric everolimus-eluting bioresorbable scaffold in ST-segment elevation myocardial infarction: Rationale and design of the BVS STEMI STRATEGY-IT study.
    Ielasi A; Varricchio A; Campo G; Leoncini M; Cortese B; Vicinelli P; Brugaletta S; di Uccio FS; Latib A; Tespili M
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):1129-1138. PubMed ID: 27774758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk and timing of clinical events according to diabetic status of patients treated with everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting stent: 2-year results from a propensity score matched comparison of ABSORB EXTEND and SPIRIT trials.
    Campos CM; Caixeta A; Franken M; Bartorelli AL; Whitbourn RJ; Wu CJ; Li Paul Kao H; Rosli MA; Carrie D; De Bruyne B; Stone GW; Serruys PW; Abizaid A;
    Catheter Cardiovasc Interv; 2018 Feb; 91(3):387-395. PubMed ID: 28471086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.